脑灰质MRI结合随机森林区分视神经脊髓炎与多发性硬化
模型区分MS与NMO平均准确率74%(敏感度/特异度77/72,p<0.01),联合丘脑体积与白质病灶体积准确率达80%。
要点
- 脑灰质影像生物标志物可区分NMO与MS,平均准确率74%。
- 丘脑体积是最具区分力的灰质指标,联合白质病灶体积准确率80%。
- MS患者深部灰质萎缩更明显,有助于与NMO鉴别。
核心结论
- 自动获取的脑灰质影像生物标志物可在两中心条件下区分NMO与MS,或有助于临床鉴别诊断。
研究设计与样本
- 计算50个皮层灰质区域的体积、厚度和表面积及深部灰质核团体积,构建3个随机森林模型分别分类NMO与MS、MS与健康对照、NMO与健康对照,以临床诊断为金标准计算准确率。
主要发现
- 分类器区分MS与NMO的平均准确率为74%(敏感度/特异度77/72,p<0.01),MS患者尤其是深部灰质萎缩更明显。
- 使用丘脑体积(最具区分力的灰质指标)联合白质病灶体积时,MS与NMO分类准确率为80%。
- MS与健康对照、NMO与健康对照的分类准确率分别为92%和88%。
临床怎么用
- 临床扫描自动获取的灰质影像标志物可用于辅助区分NMO与MS,尤其在两中心条件下验证有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We tested whether brain gray matter (GM) imaging measures can differentiate between multiple sclerosis (MS) and neuromyelitis optica (NMO) using random-forest classification. METHODS: Ninety participants (25 patients with MS, 30 patients with NMO, and 35 healthy controls [HCs]) were studied in Tehran, Iran, and 54 (24 patients with MS, 20 patients with NMO, and 10 HCs) in Padua, Italy. Participants underwent brain T1 and T2/fluid-attenuated inversion recovery MRI. Volume, thickness, and surface of 50 cortical GM regions and volumes of the deep GM nuclei were calculated and used to construct 3 random-forest models to classify patients as either NMO or MS, and separate each patient group from HCs. Clinical diagnosis was the gold standard against which the accuracy was calculated. RESULTS: The classifier distinguished patients with MS, who showed greater atrophy especially in deep GM, from those with NMO with an average accuracy of 74% (sensitivity/specificity: 77/72; p < 0.01). When we used thalamic volume (the most discriminating GM measure) together with the white matter lesion volume, the accuracy of the classification of MS vs NMO was 80%. The classifications of MS vs HCs and NMO vs HCs achieved higher accuracies (92% and 88%). CONCLUSIONS: GM imaging biomarkers, automatically obtained from clinical scans, can be used to distinguish NMO from MS, even in a 2-center setting, and may facilitate the differential diagnosis in clinical practice. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that GM imaging biomarkers can distinguish patients with NMO from those with MS.
引用
- Eshaghi A, Wottschel V, Cortese R, et al. Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest. Neurology. 2016. PMID: 27807185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。